← All trials
NCT04224207
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2019
- Primary completion
- Oct 30, 2019
- Completion date
- Jan 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 32
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ankara Universitesi TeknokentLead sponsor
- Ankara Universitesi TeknokentOverall official - principal investigator
- Ankara Universitesi TeknokentReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.